Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Merck & Co., Inc.
  6. Summary
    MRK   US58933Y1055

MERCK & CO., INC.

(MRK)
  Report
Delayed Nyse  -  04:03:09 2023-01-27 pm EST
105.38 USD   -1.39%
01/27Merck Says Keytruda Approved by FDA as Adjuvant Treatment for Non-Small Cell Lung Cancer
MT
01/27FDA Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients With Stage IB (T2a ≥4 Centimeters), II, or IIIA Non-Small Cell Lung Cancer (NSCLC)
BU
01/27Merck Announces the U.S. Food and Drug Administration has Approved KEYTRUDA
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nyse
01/23/2023 01/24/2023 01/25/2023 01/26/2023 01/27/2023 Date
109.88(c) 108.52(c) 108.59(c) 106.87(c) 105.38(c) Last
8 998 829 7 424 168 6 167 973 9 672 675 7 784 913 Volume
-0.05% -1.24% +0.06% -1.58% -1.39% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 59 119 M - -
Net income 2022 14 779 M - -
Net Debt 2022 17 558 M - -
P/E ratio 2022 17,9x
Yield 2022 2,65%
Sales 2023 58 162 M - -
Net income 2023 16 627 M - -
Net Debt 2023 9 650 M - -
P/E ratio 2023 15,8x
Yield 2023 2,82%
Capitalization 267 B 267 B -
EV / Sales 2022 4,82x
EV / Sales 2023 4,76x
Nbr of Employees 67 500
Free-Float 70,8%
More Financials
Company
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (87.8%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of... 
Read more
Sector
Pharmaceuticals
Calendar
02/02 | 06:30amEarnings Release
More about the company
Ratings of Merck & Co., Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about MERCK & CO., INC.
01/27Merck Says Keytruda Approved by FDA as Adjuvant Treatment for Non-Small Cell Lung Cance..
MT
01/27FDA Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment Following Surgical Resecti..
BU
01/27Merck Announces the U.S. Food and Drug Administration has Approved KEYTRUDA
CI
01/26Merck & Co.'s Animal Health Unit Wins US FDA Nod for Expanded Use of Flea Drug for Dogs
MT
01/26Merck Animal Health Division Says US FDA Approves Expanded Indication of Bravecto Chews..
MT
01/26Merck Animal Health Receives U.S. FDA Approval of Expanded Indication for BRAVECTO (flu..
BU
01/25Merck & Co.'s Keytruda Combo Prolongs Survival in Late-stage Biliary Tract Cancer Study
MT
01/25Merck to Cease Phase 3 Trial for Treatment of Prostate Cancer Due to Failure in Meeting..
MT
01/25Merck Reports Keytruda Phase 3 Success, Failure
DJ
01/25Merck Announces KEYNOTE-991 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Enzalutamid..
BU
01/25Merck Announces KEYNOTE-991 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Enzalutamid..
CI
01/25Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Surv..
BU
01/25Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall..
CI
01/24Merck & Company Keeps Quarterly Dividend at $0.73 a Share; Payable April 10 to Holders ..
MT
01/24Merck Announces Second-Quarter 2023 Dividend
BU
More news
News in other languages on MERCK & CO., INC.
01/27Merck : la FDA approuve une nouvelle indication du Keytruda
01/27Merck déclare que Keytruda est approuvé par la FDA comme traitement adjuvant du cancer ..
01/27Merck annonce que la Food and Drug Administration (FDA) américaine a approuvé KEYTRUDA
01/26L'unité de santé animale de Merck & Co. reçoit le feu vert de la FDA américaine pour l'..
01/26Merck : a reçu une approbation de la FDA pour BRAVECTO
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
ETFs positioned on MERCK & CO., INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
AGFiQ US Market Neutral Anti-Beta Fund - USD19.68%-2.37%United_States
ASYMshares ASYMmetric 500 ETF - USD6.28%-0.45%-NC
Invesco Dynamic Pharmaceuticals ETF - USD5.63%0.18%United_States
Nomura NEXT FUNDS International Equity MSCI...5.61%2.67%-World
VanEck Pharmaceutical ETF - USD5.21%-0.87%United_States
More ETFs positioned on MERCK & CO., INC.
Analysis
Momentum Picks: 5 stocks for the fall
Stock Pick
 MERCK & CO., INC.
A cash cow that hides some gems
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 105,38 $
Average target price 116,38 $
Spread / Average Target 10,4%
EPS Revisions
Managers and Directors
Robert M. Davis Chairman & chief executive officer
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Dave Williams EVP, Chief Information & Digital Officer
Lisa LeCointe-Cephas Chief Ethics & Compliance Officer, SVP
Thomas Henry Glocer Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.-5.02%267 180
JOHNSON & JOHNSON-4.77%439 835
ELI LILLY AND COMPANY-4.87%325 056
NOVO NORDISK A/S1.06%312 363
ROCHE HOLDING AG-0.40%277 685
ABBVIE INC.-9.49%258 606